19 In the STEP 4 withdrawal trial, patients who stopped at week 20 gained back nearly 7% of their body weight over the next 48 weeks, while those who continued the drug kept losing
Selectivity describes the endocrine response pattern in the model, not a proven benefit
The approval of Wegovy represents a turning point for healthcare providers to embrace medical management of obesity to help improve chronic weight management for patients. For more than two decades, Novo Nordisk has led the charge to translate the complex science behind obesity into medicines that can make a difference, all while partnering across industries and sectors to change how obesity is understood, diagnosed and treated, said Doug Langa, executive vice president, North America operations and president of Novo Nordisk Inc
We also performed quantitative kinetic measurements at pH 6.0 (pH 7.0 was not possible for technical reasons explained in Methods
Many people do all the right things and still lie awake